The use of opioid medications on both an acute and chronic basis is ubiquitous in the United States. As opioid receptors densely populate the gastrointestinal tract, symptoms and side effects can be expected in these patients. In the esophagus, dysmotility may result, manifesting with dysphagia and a syndrome indistinguishable from primary achalasia. In the stomach, a marked delay in gastric emptying may occur with postprandial nausea and early satiety. Postoperatively, particularly with abdominal surgery, opioid-induced ileus may ensue. In the colon, opioid-induced constipation is common. A unique syndrome termed narcotic bowel syndrome is characterized by chronic abdominal pain often accompanied by nausea and vomiting in the absence of other identifiable causes. With the recognition of the important role of opioids on gastrointestinal function, novel drugs have been developed that use this physiology. These medications include peripheral acting opioid agonists to treat opioid-induced constipation and combination agonist and antagonists used for diarrhea-predominant irritable bowel syndrome. This review summarizes the most recent data in these areas.
T he concept of pain as the fifth vital sign was introduced to draw attention to the need to provide adequate pain relief to patients. 1 The World Health Organization recommended the use of opioids for management of moderate to severe chronic cancer pain; this strategy has been adopted for patients with chronic non-cancer pain in recent years. 2 The following order of analgesic use was recommended in the World Health Organization 3-step ladder for treatment of cancer pain 3 :
Step 1: non-opioids (aspirin, acetaminophen, diclofenac, ibuprofen); then as necessary;
Step 2: mild opioids (codeine, tramadol);
Step 3: strong opioids such as morphine, buprenorphine, fentanyl, hydromorphone, methadone, and oxycodone, administered until the patient is free of pain.
Non-opioids can be added to opioids for moderate to severe pain.
Opioid Use in Chronic Non-cancer Pain
Chronic pain, defined as persistent pain for more than 3 months, 4 affects 10%-15% of the general population. 5 In patients with chronic non-cancer pain, 80% of patients experience at least 1 adverse event, with constipation (41%), nausea (32%), and somnolence (29%) being most common. 6 Overall, the prevalence of opioid-induced constipation (OIC) varies from 41% to 81%. 6, 7 In the United States, 4% of adults are taking chronic opioid therapy, chiefly for non-cancer pain, including 4.1% in a population study in Olmsted County, Minnesota. 8 The most common indications for opioid use in non-cancer pain were musculoskeletal (eg, back, degenerative joint disease, fibromyalgia), post-surgery, and vascular pain. 8 Opioids are more effective than non-opioid analgesics in controlling moderate to severe pain. Thus, w90% of patients with moderate to severe pain are treated with opioids. 9 An estimated 20% of patients presenting to physicians' offices with pain symptoms in the United States are prescribed opioids. 10 The Centers for Disease Control estimates that the reason for opioid-related overdosing is overprescription of opioids by healthcare providers.
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Because w4% of adults in the United States are on opioids for at least 3 months for chronic non-cancer indications, there are several public health initiatives 12 aimed at reversing the epidemic of opioid use for different pain indications and the rising tide of deaths from opiates.
Types of Opioid Receptors: Mu, Delta, Kappa
Opioid receptors are G(i/o) G-protein coupled receptors that regulate several functions including pain, reward, mood, stress, gastrointestinal functions, and respiration. The 3 main opioid receptors (m, d, k) 14 show a high degree of sequence homology and a common opioid receptor binding pocket within a helical transmembrane core. 15, 16 The main differences in sequence between the receptors occur in the extracellular domains, which contributes to ligand selectivity. 17 The opioid peptides reduce intracellular cyclic adenosine monophosphate by inhibiting adenylate cyclase. At the membrane level, they reduce neuronal excitability by hyperpolarization resulting from increased potassium permeability of the membrane and neurotransmitter release by inhibition of voltage-gated calcium channels. 18 The overall effect at the cellular level is thus inhibitory, resulting in a reduction in acetylcholine release, with overall inhibitory effect on the neuron.
Opioid receptors are widely distributed in the central and peripheral nervous system, the intestinal musculature, and other tissues including the dorsal horn of the spinal cord where they process and relay afferent nociceptive signals to the central nervous system. 19 In the brain, opioid receptors are mainly in areas involved in pain transmission: the thalamolimbic system, the periaqueductal grey matter, the rostral ventral medulla, the nucleus paragigantocellularis lateralis, and the locus ceruleus. 20 The pharmacologic and potential clinical effects of organ-specific opioid stimulation are summarized in Table 1 .
The m receptors are the principal mediators of analgesic action of endogenous and exogenous opioids, as well as the major side effects of sedation, bowel dysfunction, respiratory depression, and dependence. 21 The k receptors also mediate analgesia; other effects include bowel dysfunction, increased diuresis, and sedation. 22 The k agonists may relieve hyperalgesia produced by chronic use of m opioid receptor therapies. 23 However, the central activation of k opioid receptors produces dose-dependent dysphoria, and some agonists, such as salvinorin A, produce hallucinations. 24 The d receptors are predominantly in the central nervous system where they produce analgesia, but they are also found in myenteric and submucosal neurons of the gut; their action results in inhibition of motility and secretion. 19 The m and d receptors are the principal opioid receptors in the gastrointestinal tract, and they are expressed predominantly in the submucosal and myenteric plexuses, respectively. 25 Table 2 summarizes endogenous and exogenous mediators (focused on currently available medications) of the 3 major opioid receptor types and their general effects on gastrointestinal motor and sensory functions.
Because the clinically relevant opioids are m opioids, this update focuses on m opioid receptors.
Gastrointestinal Effects of m Opioids
Opioids have pharmacologic effects throughout the gastrointestinal tract. They decrease gastric emptying and stimulate pyloric tone, 26 inhibit propulsion, increase amplitude of non-propulsive segmental contractions, increase fluid absorption in the small and large intestine, increase anal sphincter tone, 27 and impair reflex relaxation of the anal sphincter in response to rectal distention. The acute effects of opioids on esophageal function are not as clear. Two studies have demonstrated an acute decrease in lower esophageal sphincter (LES) pressure by m opioid receptor stimulation. 28, 29 Nevertheless, the sum of these motor and secretory effects results in anorexia, nausea, emesis, impaired ability to evacuate the bowel, as well as abdominal spasm, cramps, and pain. 19, 30 Decreased gastric, biliary, pancreatic, and intestinal secretions interfere with digestion.
Differences in Acute Versus Chronic Mu Opioid Effects in the Gastrointestinal Tract
One of the characteristics of m opioid effects is the development of tolerance, which results in the need for increasing doses of opioids to achieve the same effects, such as on analgesia or euphoria. This tolerance develops from a desensitization in which opioid receptor stimulation by an agonist leads to lower signal transduction and effector response. 31 The effects of chronic opioids on the gut similarly derive from the effects of generalized tolerance but also differ because of the differential tolerance of gut regions to m opioids. For example, tolerance to the effects of m opioids 32, 33 occurs in all gastrointestinal organs except in the colon. 34 Therefore, effects such as constipation do not abate over time. These differences may also reflect varying densities of opiate receptors that are organ specific in the gut. 35 The exact mechanism of tolerance in humans is unclear, although the prevailing hypotheses are either dephosphorylation, which leads to activation of the receptor to bind an agonist, 14 or binding of b-arrestin-2, which causes receptor internalization in the endosome, prolonging the desensitization of the receptor. 36 Internalization of the opioid receptors may also occur. The downregulation of b-arrestin-2 does not occur in the ileum, thus causing tolerance to morphine, but this is not observed in the colon, which leads to receptor recycling to the plasma membrane and, hence, lack of tolerance in the colon and development of OIC. 17 Finally, the different downstream effects of stimulating an opioid receptor may follow different time courses of dependence, also leading to variation in gut effects. 31 Mu Opioids, Gastrointestinal Symptoms and Syndromes
Esophageal Motility Disorders
Mu opioids may be associated with dysphagia or heartburn that may reflect intrinsic neural or sphincter dysfunction.
In patients with gastroesophageal reflux disease, 37 acute morphine administration significantly decreases the rate of transient LES relaxations in patients vs controls, resulting in less reflux episodes and a decrease of the time at pH <4. Resting LES pressure is decreased both in health and in achalasia; swallow-induced LES relaxation is also significantly decreased by morphine in the healthy subjects. 29 A range of manometric abnormalities have been reported in patients with dysphagia who were using chronic opioids such as impaired LES relaxation, high amplitude/velocity, and simultaneous esophageal waves, 38 as well as esophagogastric junction outflow obstruction, higher integrated relaxation pressure, and lower distal latency on esophageal pressure topography. 39 Some of these findings are in contrast to the acute opioid effects cited previously. This suggests a different esophageal physiology with acute and chronic usage. There may also be clinical and manometric features that mimic type 3 and less so, type 2 achalasia. As many of these patients cannot stop and/ or require chronic opioid treatment, it is problematic to determine whether the achalasia is primary or secondary to opiates. There is some evidence that treatment outcome is worse in those with clear opioid-induced achalasia. 40 
Nausea and Emesis
Opioid administration can induce nausea or vomiting, and this is commonly seen in the postoperative period, with opioids being one factor in the multifactorial etiology. 41 The pathophysiology involves, in part, peripheral inhibitory effects of opioids on gastrointestinal transit or the stimulation of the pyloric sphincter, which delays gastric emptying or causes gastroparesis. However, the primary mechanism of opioid-induced nausea and emesis is central, with direct stimulation of the chemoreceptor trigger zone in the area postrema in the floor of the fourth ventricle. 42 NK-1 receptors in the area postrema are involved in the mechanism underlying morphine induced emesis in ferrets, 43 although there are no reports of aprepitant, an NK-1 antagonist, on nausea, even though it reverses other effects of oxycodone. 44 The clinical efficacy of 5-HT 3 antagonists for opioid-induced emesis supports the hypothesis that stimulation of the area postrema may also be relevant in morphine-induced emesis in humans. 45 Adding a prokinetic (eg, metoclopramide), prochlorperazine, or a 5-HT 3 antagonist to the opiate regimen is beneficial, especially in a postoperative pain control setting. 
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Gastroparesis
Peripheral inhibitory effects of opioids on antral motility or the stimulation of the pyloric sphincter 25 result in delayed gastric emptying or cause gastroparesis. Among patients evaluated for gastroparesis by the National Institutes of Health Gastroparesis Consortium, 42% overall 49 and 48% of those with abdominal discomfort score !3 and 33% of those with score <3 were on opiates/narcotics. 50 It is important to note that even novel opioid agents that appear to induce less constipation when used chronically may retard gastric emptying. Tapentadol (a mu opioid receptor agonist and norepinephrine reuptake inhibitor) was associated with delayed gastric emptying comparable to the effect of oxycodone. 51 Although tramadol was reported not to retard gastric emptying of solids or liquids in a crossover study of 12 healthy participants, the same study showed 40% slower orocecal transit and significant delay in colonic transit. 52 Tramadol induced dose-related inhibition of gastrointestinal transit in mice. 53 
Sphincter of Oddi
Opiates may have important effects on sphincter of Oddi function. The effects of opioids on the sphincter are predominantly myogenic, as evidenced by preservation of their effect on sphincter pressure in the presence of the neurotoxin tetrodotoxin. 54 Furthermore, different opioid receptors may modulate sphincter of Oddi function. This is suggested by a specific increase in tonic pressure by morphine but an increase in phasic sphincter pressure by naloxone. 55 Nevertheless, the predominant effect of clinically used opioids appears to be an increase in sphincter of Oddi phasic pressure. 56 In a retrospective study of post-cholecystectomy patients with suspected sphincter of Oddi dysfunction (SOD), 30% had taken opiate-containing drugs 15-120 minutes before the onset of pain, suggesting that opiates may have been the cause of the SOD. 57 Likewise, eluxadoline, a mixed m opioid receptor agonist-d opioid receptor antagonist and k opioid receptor agonist recently approved for the treatment of diarrhea-predominant irritable bowel syndrome (IBS), has been associated with SOD in a small percentage (w0.5%) of patients without a gallbladder. 58 This was confirmed in a more recent study of nearly 2000 patients with diarrheapredominant IBS, with 10 patients developing sphincter of Oddi spasm, most at the higher eluxadoline dose of 100 mg. 59 In a recent communication (https:// www.fda.gov/Drugs/DrugSafety/ucm546154.htm), the U.S. Food and Drug Administration (FDA) issued a warning that eluxadoline should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. In the communication dated March 15, 2017 , the review showed that as of February 2017, two deaths were reported to the FDA in two patients with prior cholecystectomy on eluxadoline. One death was associated with pancreatitis, with symptom onset within 1 hour of taking a single dose of eluxadoline, and the other death was associated with sphincter of Oddi spasm, manifested as severe abdominal pain and vomiting shortly after taking the first dose of the drug.
Postoperative Ileus and Opioids
Opioids are a mainstay of pain relief after abdominal surgery, and they inhibit gastrointestinal and colonic motility. Postoperative ileus is a complex disorder, and major intrinsic contributing factors include surgical stress (ie, from handling the bowel), secretion of inflammatory mediators and endogenous opioids in the gastrointestinal tract, and changes in hormone levels and electrolyte and fluid balance.
19,60
Opioid-induced Constipation
The m opioids increase fluid absorption and inhibit motility in the colon. OIC is generally defined as a change from baseline in bowel habits and change in defecation patterns after initiating opioid therapy, which is characterized by any of the following: reduced frequency of spontaneous bowel movement (SBM) (<3 bowel movements/week), worsening of straining to pass bowel movement, sense of incomplete evacuation, and harder stool consistency. 61 These features have been recently adopted in Rome IV criteria (Table 3) . 62 OIC can occur even at low dosages of opioids 63 and at any time after initiation of opioid therapy. 64 Nausea, vomiting, and gastroesophageal reflux are commonly associated with OIC. 65 The bowel function index (BFI) is a clinician assessment tool to appraise severity and responsiveness to current treatment. It includes ease of defecation, feeling of incomplete bowel evacuation, and personal judgment of constipation (Figure 1) . Each variable is rated by the patient from 0 to 100 on the basis of the experience in 7 days. 66 The reference range of BFI scores for non-constipated patients from 0 to 28.8 provides a simple discrimination between constipated and nonconstipated patients on opioid therapy. 67 A BFI !30 is recommended as a criterion to identify patients on laxatives for whom prescriptions of FDA-approved therapies for OIC are justified. 68 
Narcotic Bowel Syndrome
Narcotic bowel syndrome (NBS) is described as persistent moderate to severe daily abdominal pain of more than 3 months' duration occurring in patients requiring more than 100 mg morphine equivalent per day; the abdominal pain does not respond and may actually increase in response to escalating doses of narcotics. 69 It is to be differentiated from the general causes of pain in patients on opiates because it is a disease of nociception independent of the opioid effects on gut motility and secretion. 70 It is likely a more common syndrome than realized, but a 2009 epidemiologic study in Olmsted County estimated the prevalence at 4%. 8 There are at least 5 postulated mechanisms or hypotheses to explain this paradoxical increase in pain. The precise interaction of these diverse mechanisms in production of pain in NBS is unclear. The diagnosis of NBS is suggested by the presentation of a patient on chronic opiates with chronic generalized, colicky abdominal pain, despite escalating doses of opiates, and worsening of pain with tapering of the dose. The pain may be associated with nausea and vomiting. An extensive negative evaluation usually ensues. Emergency evaluation is commonly sought for pain control and to evaluate for causes of abdominal pain that may be found in these patients such as kidney stones and bowel obstruction. 73 Treatment of NBS is difficult, requiring detoxification with substitution of opioids with non-opiate medications to control pain, anxiety, and opiate withdrawal symptoms, including the use of clonidine. This is best handled through specialists and/or centers with expertise in opiate dependence. 69 Although there is a high recidivism rate (approximately 50%), those who remain off of narcotics report improvement in pain. 72 
Acute Abdominal Pain in Patients on Chronic Mu Opioid Treatment
Recent data show that among the non-cancer patients attending the Mayo Clinic Emergency Department with acute abdominal pain, w19% (442 of 2354) were on m opioid agonists for more than 3 months for chronic pain. The indication for the opioids was abdominal pain in 21% of these patients (93/442), suggesting that despite the lack of evidence of efficacy or safety, m opioid agonists are being prescribed for patients with non-cancer--related abdominal pain, which likely includes IBS. 73 
Therapeutic Uses of Opioid Receptor Agonists and Antagonists in Gastroenterology
Opioid Agents in Treatment of Functional Gastrointestinal Diseases
Mu opioid agonists. Loperamide, a synthetic peripheral mu opioid receptor agonist, is efficacious in the treatment of diarrhea in IBS patients, delaying intestinal transit, 74 significantly decreasing stool frequency, increasing water and ion absorption, and improving stool consistency and urgency. 75 Its advantage over other m opioids such as codeine or diphenoxylate is that it does not cross the blood-brain barrier. Loperamide may also result in improvement in anal sphincter tone. 76 Generally, loperamide compared with placebo does not have a significant effect on the perception of pain in IBS patients, although pain associated with attacks of diarrhea may be reduced. 77, 78 The typical doses of loperamide are 2 mg after each loose bowel movement (usually <8 mg per day) or preprandial 2-4 mg in IBS patients with prominent diarrhea after feeding.
As a group, the m opioid agonists were used for pain relief during acute exacerbations of pain in patients with IBS in a combined European and U.S. study, which documented use of opioids in 35% of attacks either alone or in combination with other drugs. 79 In this retrospective study, diarrhea-predominant IBS patients were more likely to use opioids during pain attacks (32% of attacks) than patients with IBS with constipation (20% of attacks) or mixed IBS (19% of attacks). There are no randomized, controlled trials of the use of m opioid agonists in the treatment of chronic pain in patients with IBS. It is important to reiterate that there is no evidence for use of m opioid agonists for the pain of IBS.
A mixed opioid agent, eluxadoline. Eluxadoline is a m and k opioid receptor agonist and d opioid receptor antagonist with minimal oral bioavailability. At 100 mg and 200 mg, eluxadoline resulted in greater improvements in bowel movement frequency and urgency, global symptoms, IBS Symptom Severity Score, IBS quality of life, and adequate relief. 80 Results on the primary efficacy end point (combined bowel function and pain) were generally confirmed in pivotal trials with a number needed to treat of w8, 58 although abdominal pain scores were not significant for the 75 or 100 mg doses. The adverse events of pancreatitis and sphincter of Oddi spasm, each in 0.3% of patients in the controlled trials, led to exclusions from treatment of patients with a history of bile duct obstruction, pancreatitis, severe liver impairment, or severe constipation and intake of more than 3 alcoholic beverages per day. An updated analysis of safety of eluxadoline in the phase 2 and 3 trials shows that clinically apparent sphincter of Oddi spasm events were observed in eluxadoline-treated patients without a gallbladder, and the majority were observed with the higher (100 mg) dose of eluxadoline. 59 The FDA Adverse Event Reporting System received information of 99 cases of pancreatitis and 39 cases of sphincter of Oddi spasm within 10 months of the availability of eluxadoline in the United States. 81 
Treatment of Opioid-associated Postoperative Ileus: Alvimopan
Alvimopan is a peripherally acting mu opioid receptor antagonist (PAMORA) approved in the United States for management of postoperative ileus in patients after bowel resection. Alvimopan can accelerate recovery of gastrointestinal function (especially for the lower gastrointestinal tract), shorten the length of hospital stay, and reduce postoperative ileus-related morbidity without compromising opioid analgesia in an enhanced recovery setting. 79 A recent meta-analysis of 9 randomized, controlled trials involving 4075 patients demonstrated that alvimopan significantly decreased the time to first passage of stool postoperatively and lowered the chance of serious side effects. 82 
Prevention and Treatment of Opioid-induced Constipation
Choice of medication to prevent opioid-induced constipation. Oxycodone and naloxone. Naloxone is a relatively nonselective opioid antagonist used intravenously to treat opioid overdosing. When administered orally, standard formulation naloxone acts locally on m opioid receptors in the gastrointestinal tract. 83 Naloxone improved symptoms of OIC and reduced laxative use with only mild opioid withdrawal symptoms such as yawning, sweating, and shivering. 84 Prolonged release (PR) naloxone has extensive firstpass metabolism (hepatic glucuronidation), which reduces its bioavailability for systematic action to <2%. Naloxone PR reduced mean colonic transit time by 2.1 hours when used in combination with oxycodone PR (20 mg oxycodone/10 mg naloxone) compared with oxycodone PR alone (20 mg). 85 Oxycodone PR and naloxone PR in combination (fixed ratio 2:1, approved at maximum dose of 40 and 20 mg, respectively) are superior to PR oral oxycodone alone to treat OIC. 86 Naloxone displaces oxycodone from the gastrointestinal m opioid receptors, with negligible action in the systemic circulation because of high first-pass metabolism. In contrast, the bioavailability of oxycodone is 80%; therefore, its analgesic action mediated in the central nervous system is preserved. 87 When compared with oxycodone alone, the combination of oxycodone PR and naloxone PR decreased BFI scores by 48.5 units (on 0-100 scale), increased the median number of complete SBMs/week 3-fold and improved constipation-related quality of life. [88] [89] [90] The most common adverse effects were nausea, vomiting, headache, constipation, and diarrhea, 91 with 13% incidence of severe adverse events.
Tapentadol. Tapentadol is a m opioid agonist and norepinephrine reuptake inhibitor 92 ; the latter function adds to the analgesic potential of the m opioid agonists, predominantly through stimulation of a 2 -adrenergic receptors. 93 The combined effects of tapentadol on pain sensation can be achieved with a relatively lower level of m opioid agonist to achieve analgesia equal to that of oxycodone, with reduced gastrointestinal adverse effects such as constipation in chronic painful conditions such as moderate to severe chronic osteoarthritis-related knee pain 94 or moderate to severe chronic low back pain. 95 However, acutely administered tapentadol slows gastric emptying similarly to oxycodone, although it does not retard colonic transit. 51 
Over-the-counter Laxatives and When to Move to Specific Prescription Treatments
Because laxatives were proven to be effective in some patients, 96 they should be the first-line treatment in patients with diagnosis of OIC. Guidelines from the European Association for Palliative Care recommend laxatives for the prophylaxis or management of OIC in patients with cancer. 97 Unfortunately, prophylactic treatment to prevent constipation is seldom prescribed to outpatients who receive prescription opioids. 98, 99 A prospective, open-label study suggests that polyethylene glycol (13.81 g daily) and sodium picosulfate (10 mg daily) are more efficacious than lactulose 100 for outpatients with cancer on opioid therapy.
Recent studies have documented inadequate response of OIC to laxative treatment. 101 If there is insufficient clinical benefit with laxatives, as evidenced by a BFI score >30 points, treatment with medications approved for OIC should be considered (PAMORA, combination of oxycodone and naloxone, lubiprostone). Reassessment of the BFI score is useful to monitor improvement in OIC. 68 Treatment of opioid-induced constipation. Intestinal secretagogue: lubiprostone. Lubiprostone is a bicyclic fatty acid derived from prostaglandin E 1 metabolite that increases fluid secretion in the gastrointestinal tract 102 by stimulating the cystic fibrosis transmembrane regulator and type 2 chloride channels in the apical membrane to secrete chloride and water into the lumen, resulting in laxation and acceleration of small intestinal and colonic transit. 103 In patients with OIC, Lubiprostone compared with placebo increased the overall frequency of SBMs/week and reduced the time to first bowel movement by 50%. 104, 105 In these same trials, lubiprostone significantly improved constipation symptoms such as abdominal discomfort, degree of straining, stool consistency, and constipation severity. Nausea, diarrhea, and abdominal pain were the most common side effects.
Lubiprostone-stimulated secretion of Cl -ions via type 2 chloride channels was inhibited in vitro in T84 cell lines by methadone. 106 As a result of these studies, lubiprostone is contraindicated in OIC associated with methadone use. Lubiprostone, 24 mg twice daily, was approved by the FDA for OIC in patients with non-cancer pain.
Peripherally acting mu opioid receptor antagonists: methylnaltrexone and naloxegol. Methylnaltrexone is a quaternary N-methyl derivative of naltrexone 107 ; the methyl group decreases the lipid solubility and increases polarity, preventing it from crossing into the brain. 108 Peripherally administered methylnaltrexone decreased morphine-induced delay in orocecal transit time. 109 In a 4-week trial of methylnaltrexone, 12 mg once daily or every other day compared with placebo in patients with OIC, there was significantly shortened time to first rescue-free bowel movements, increased the number of weekly rescue-free bowel movements, improved degree of straining, decreased sense of incomplete evacuation, and improved Patient Assessment of Constipation Quality of Life 110 ; an early response suggested excellent outcome. Another trial with same doses improved Patient Assessment of Constipation Symptom scores, specifically the stool and rectal symptoms, with no effect on pain scores. 111 Abdominal pain and nausea were the most common adverse events reported; other adverse effects were diarrhea, hyperhidrosis, and vomiting. The FDA has approved 12 mg subcutaneous injection of methylnaltrexone for the treatment of OIC in patients taking opioids for chronic, non-cancer pain. There have been 7 cases of gastric or intestinal perforation reported in the FDA Adverse Event Reporting System in association with methylnaltrexone therapy for OIC during the first 18 months after approval. 112 The causative relationship has not been established, because patients either had coincidental gastric ulcer or severe constipation, which is itself a risk factor for perforation.
Naloxegol is a pegylated derivative of naloxone 113 that does not cross the blood-brain barrier. In addition, P-glycoprotein transporter transports naloxegol from the central nervous system. 114 Only negligible amounts of naloxegol reach the central nervous system; therefore, it does not reduce pain relief from opioids. Naloxegol antagonized morphine-induced reduced orocecal transit, but it had no effects on miosis or opioid withdrawal symptoms, suggesting exclusively peripheral action. 113, 115 Large 12-week phase II and phase III studies all showed naloxegol improved SBMs from the first week of treatment, 115, 116 even in patients with inadequate response to laxatives. In these trials, naloxegol improved stool consistency, complete SBM, percentage of days with straining, Patient Assessment of Constipation Symptoms, and Patient Assessment of Constipation Quality of Life and was well-tolerated and safe.
In patients with OIC, an improvement in the frequency of SBMs by !3 per week was associated with consistent improvements in patient response outcomes, that is, Patient Assessment of Constipation Quality of Life and Patient Assessment of Constipation Symptoms at each study visit and the Straining Scale and stool consistency or form (Bristol Stool Scale) with each bowel movement. 117 From the United Kingdom's National Health Service and Personal Social Service perspective, a recent analysis suggests that naloxegol treatment is costeffective in patients with OIC who are not responding to laxatives. 118 When administered for 52 weeks in OIC patients with non-cancer pain, 119 the most common side effects were abdominal pain, diarrhea, nausea, headache, and flatulence; no QT/QTc interval prolongation or serious adverse events occurred. The FDA approved naloxegol at 12.5 or 25 mg 4 times a day orally for OIC in adults with chronic noncancer pain but requires that patients be monitored for adverse cardiovascular events. A summary of medication trials used for OIC is given in Table 4 .
Conclusion
Opioid medications are commonly used in clinical practice and have acute or chronic effects on diverse parts of the gastrointestinal tract. Because of their widespread use, it is imperative to consider whether any presentation with gastrointestinal symptoms may be related to the intake of opioids. Acute administration of opioids should be accompanied by symptomatic remedies to counter the acute pharmacologic effects, and these include antiemetics and laxatives. The BFI is a useful clinical tool to identify chronic OIC that is not responding satisfactorily to first-line therapies and to select patients for treatment with prescription medications approved for the treatment of OIC.
